Please Note:
This profile was automatically generated using 4 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 4 references found on the Internet. This information has not been verified. Learn more...
Web References
-
1. Venture One Outlook | Past Events
ventureoneoutlook.dowjones.com - [Cached]Published on: 3/22/2006 Last Visited: 8/9/2007
Uri Danon, Chief Executive Officer, AtoxBio
...
Uri Danon, Chief Executive Officer -
2. Globes [online] - Defend and protect
www.globes.co.il/serveen/globe - [Cached]Published on: 8/11/2005 Last Visited: 11/10/2005
This overreaction can lead to severe physical problems and even death, says Atox Bio CEO Uri Danon.
...
"During the 1990s, many companies tried to find drugs to treat this problem," says Danon, "but only one had any degree of success, and it can only successfully treat 6% of patients.
...
Danon says that this third receptor was uniform for all superantigen attachments to T-cells.
...
Danon was previously project manager that developed the Copaxone chemical solution for Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA). He is now applying his know-how to create partnerships and an outsourcing network for Atox Bio. -
3. Globes [online] - Hebrew U gets $5.6m US biodefense grant
www.globes.co.il/serveen/globe - [Cached]Published on: 9/22/2005 Last Visited: 9/25/2005
"The grant will fund development of Atox Bio's drug for biodefense, using a shortened pathway towards FDA approval that requires only the completion of Phase I clinical trials for licensure," said Atox Bio CEO Uri Danon.

